Sarepta Therapeutics Inc (NASDAQ:SRPT) Surpasses Q2 2025 Estimates with Strong ELEVIDYS Performance

Last update: Aug 6, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Beats Q2 2025 Estimates as ELEVIDYS Drives Revenue Growth

Sarepta Therapeutics Inc (NASDAQ:SRPT) reported strong second-quarter 2025 financial results, surpassing analyst expectations on both revenue and earnings per share (EPS). The company’s performance was bolstered by robust sales of its gene therapy ELEVIDYS, along with milestone payments from its collaboration with Roche.

Financial Performance vs. Estimates

Revenue: $611.1 million, up 68% year-over-year and significantly above the consensus estimate of $540.6 million.
EPS: $2.02, well ahead of the estimated $0.75.
Cash Position: Total cash, cash equivalents, and investments increased by $202.8 million from the prior quarter, reaching $1.36 billion.

The revenue surge was primarily driven by:

ELEVIDYS Sales: Net product revenue for the gene therapy rose by $160.1 million due to expanded label approval in June 2024.
Collaboration Revenue: A $63.5 million milestone payment from Roche for ELEVIDYS’s regulatory approval in Japan contributed to the outperformance.

Market Reaction

Following the earnings release, SRPT shares rose 5.4% in after-hours trading, reflecting investor optimism. The stock had been under pressure in recent weeks, declining 16% over the past month, likely due to concerns around ELEVIDYS’s temporary shipment pause for non-ambulatory patients. However, the FDA’s recent decision to lift the pause for ambulatory patients and the company’s strong financials appear to have restored confidence.

Key Corporate Developments

ELEVIDYS Update
- The FDA lifted its voluntary pause on shipments for ambulatory Duchenne patients after reviewing safety data.
- Discussions are ongoing regarding risk-mitigation strategies for non-ambulatory patients.
Strategic Restructuring
- Sarepta announced a restructuring plan expected to reduce annual expenses by $400 million starting in 2026, focusing on high-priority programs like its siRNA platform.
Pipeline Progress
- SRP-1001 (FSHD): Phase 1/2 data expected in H2 2025.
- SRP-1003 (DM1): Preliminary Phase 1 data anticipated in late 2025.
- SRP-1004 (SCA2): Enrollment progressing, with Cohort 2 expected in Q3 2025.
- SRP-1005 (Huntington’s Disease): Clinical trial application (CTA) filing planned by year-end.

Outlook vs. Analyst Estimates

While Sarepta did not provide explicit forward guidance, analysts project:

Q3 2025 Revenue: $351.4 million (vs. no official company forecast).
Full-Year 2025 Revenue: $1.97 billion.

The company’s cost-saving measures and strong commercial execution suggest it is well-positioned to meet or exceed these estimates.

Conclusion

Sarepta’s Q2 results demonstrate strong execution, with ELEVIDYS driving revenue growth and the pipeline advancing key milestones. The market’s positive reaction indicates renewed confidence in the company’s ability to navigate regulatory challenges and sustain growth.

For more detailed earnings and estimates, visit Sarepta’s earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research before making any financial decisions.